Table 4.

Summarized results of the interaction effect analysis

Interaction effects	BP	DVT	LAD	PE	IS	TP
T2DM×(mRNA-1273) (reference: T2DM× JNJ-78436735)	1.26 (0.40–3.97)	0.80 (0.22–2.91)	1.44 (0.46–5.42)	0.58 (0.20–1.65)	1.68 (0.32–10.16)	0.15 (0.02–0.80)a
T2DM×(BNT162b2) (reference: T2DM× JNJ-78436735)	2.17 (0.67–7.08)	4.69 (1.26–18.77)a	1.67 (0.54–6.24)	2.78 (0.90–8.86)	2.54 (0.45–16.84)	0.21 (0.02–1.34)
T2DM×(mRNA-1273) (reference: T2DM× BNT162b2)	0.58 (0.31–1.07)	0.17 (0.06–0.46)b	0.87 (0.60–1.25)	0.21 (0.08–0.48)b	0.66 (0.19–2.18)	0.72 (0.17–3.08)

The odds ratio was calculated by multiple logistic regression analysis for each severe adverse event after adjusting for sex (reference: female), age, onset days, and vaccine type (reference: JNJ-78436735) as covariates. In the case of cerebral venous sinus thrombosis and encephalitis myelitis encephalomyelitis, the frequency of occurrence was very small (10 or less, respectively); therefore, the results are not presented in the table.

BP, Bell’s palsy; DVT, deep vein thrombosis; LAD, lymphadenopathy; PE, pulmonary embolism; IS, ischemic stroke; TP, thrombocytopenia; T2DM, type 2 diabetes mellitus.

^aP<0.05,

^bP<0.001.